Immunovia has announced that the company’s President and Chief Executive Officer, Patrik Dahlen, has informed the Board of Directors of his intention to step down, for personal reasons.
The search for a new CEO will start immediately, states the company. Patrik Dahlen will remain with the company for another six months to ensure an orderly transition.
“Immunovia is a fantastic company with an important mission and solid strategy. It is a privilege to work with such knowledgeable and committed colleagues. For personal reasons I will not be able to be a part of the journey ahead, which I regret. But I am confident that Immunovia will continue to successfully break new ground in the future,” says Patrik Dahlen.
“Immunovia’s mission is to detect and prevent pancreatic cancer, one of the deadliest cancer forms there is. Today, we stand stronger than ever with our pioneering IMMray PanCan-d test. Bringing us here has been a team effort, where Patrik has played a crucial role and achieved regulatory approval and launched the product, which is now available throughout the United States. We are now penetrating this prioritized market according to our strategy and will continue to do so with full focus. On behalf of the Board, I thank Patrik for this outstanding effort,” says Carl Borrebaeck, chairman of the Board of Directors.
Read more: Immunovia – Nordic Life Science Star 2021
Photo of Patrik Dahlen: Immunovia